Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M

Harmony Biosciences Holdings, Inc.

Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.
Cash and equivalents $50.6M at Dec 31, 2022; sufficient to fund operations to mid-2024 per management.
Acquisition closed Oct 10, 2023; pro forma combined statements filed as Exhibit 99.3 (not included in this text).
Zynerba clinical-stage pipeline targets FXS and 22q deletion syndrome; deferred Phase 3 ASD program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.